New and updated respiratory syncytial virus (RSV) resources
Home / News & Opportunities / Latest news / Current post
August 13, 2025
The Australian Government Department of Health, Disability and Aging (the department) has released a number of updated resources to support the correct administration of RSV vaccines and monoclonal antibodies.
A single dose of the RSV vaccine, Abrysvo®, is recommended for women at 28 to 36 weeks of pregnancy and is available for free through the National Immunisation Program (NIP).
- Arexvy® must not be administered to pregnant women.
- Victoria is offering the RSV monoclonal antibody, Beyfortus™ (Nirsevimab) for free to eligible infants and children.
- Abrysvo® and Arexvy® must not be administered to infants or children.
- The department has produced a poster outlining the correct administration of RSV vaccines and monoclonal antibodies by cohort.
Updated resources include:
- RSV vaccine and monoclonal antibody poster – to facilitate appropriate choice of product
- RSV provider advice fact sheet
- RSV consumer advice fact sheet
- RSV frequently asked questions fact sheet.
For more information visit - Respiratory syncytial virus (RSV) vaccine | Australian Government Department of Health, Disability and Ageing
Latest news
New community resource kit providing ready-to-share information on the recent changes to bulk billing and how to find your nearest bulk billing practice.
New statewide referral criteria for 12 children’s orthopaedics conditions came into effect on 20 April 2026 in all Victorian public hospitals. The children’s orthopaedics suite joins 20 suites of specialist referral criteria already in existence across Victoria.
A statewide investigation has found no evidence of an increased risk of giant cell arteritis (GCA) following COVID-19 vaccination, providing reassurance for clinicians counselling patients about vaccine safety.
